IMC 4011
Alternative Names: IMC-4011Latest Information Update: 28 Aug 2026
At a glance
- Originator ImmuneCyte
- Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
- 19 Jul 2022 Preclinical trials in Breast cancer in USA (Parenteral), prior to July 2022 (Immunecyte pipeline, July 2022).)